AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19383058 — intervention group
Group type: EXPERIMENTAL
Intervention: All beta-blocker treatments
Number of subjects: 11
Study 17667485 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated/acutely ill PBD patients
Number of subjects: 86
Study 17667485 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated/clinically stabilized PBD patients
Number of subjects: 86
Study 17667485 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 86
Study 17667485 — intervention group
Group type: EXPERIMENTAL
Intervention: PBD subjects with comorbid ADHD
Number of subjects: 86
Study 17667485 — intervention group
Group type: EXPERIMENTAL
Intervention: PBD subjects without ADHD
Number of subjects: 86
Study 15592053 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow shock wave lithotripsy (SWL) rate (60 pulses per minute)
Number of subjects: 156
Study 15592053 — intervention group
Group type: COMPARATOR
Intervention: Fast shock wave lithotripsy (SWL) rate (120 pulses per minute)
Number of subjects: 156
Study 11849202 — intervention group
Group type: EXPERIMENTAL
Intervention: Test mucoadhesive solution (TS)
Number of subjects: 20
Study 11849202 — intervention group
Group type: COMPARATOR
Intervention: Reference commercial solution (RS)
Number of subjects: 20
Study 10634389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate
Number of subjects: 390
Study 10634389 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene - 60 mg/day
Number of subjects: 390
Study 10634389 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene - 120 mg/day
Number of subjects: 390
Study 10634389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 390
Study 10634389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 9193219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide powder (800 micrograms or 400 micrograms daily)
Number of subjects: 126
Study 9193219 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal or a single injection of sustained released betamethasone (for failed therapy)
Number of subjects: 126
Study 9193219 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (monitoring phase after treatment)
Number of subjects: 126
Study 1487547 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 6
Study 1487547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 6
Study 1487547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3532680 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered postoperative prophylactic positive expiratory pressure (S-PEP)
Number of subjects: 75
Study 3532680 — intervention group
Group type: COMPARATOR
Intervention: Control group (face-mask set without resistance)
Number of subjects: 75
Study 30476246 — intervention group
Group type: COMPARATOR
Intervention: 8L:16D
Number of subjects: 480
Study 30476246 — intervention group
Group type: COMPARATOR
Intervention: 14L:10D
Number of subjects: 480
Study 30476246 — intervention group
Group type: COMPARATOR
Intervention: ≥12 h photoperiods
Number of subjects: 480
Study 30060912 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard consent plus visual aid
Number of subjects: 0
Study 30060912 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical consent
Number of subjects: 0
Study 27908282 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-management arm (multidimensional geriatric assessment and tailored interventions)
Number of subjects: 1200
Study 27908282 — intervention group
Group type: COMPARATOR
Intervention: Usual-care arm (standard oncological care based on pre-defined oncological protocols)
Number of subjects: 1200
Study 25399733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood-pressure target (95/60 to 110/75 mm Hg)
Number of subjects: 558
Study 25399733 — intervention group
Group type: COMPARATOR
Intervention: Standard blood-pressure target (120/70 to 130/80 mm Hg)
Number of subjects: 558
Study 23168367 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOEP-14 (conventional chemotherapy with rituximab)
Number of subjects: 275
Study 23168367 — intervention group
Group type: COMPARATOR
Intervention: R-MegaCHOEP (high-dose chemotherapy with rituximab)
Number of subjects: 275
Study 23168367 — intervention group
Group type: COMPARATOR
Intervention: R-MegaCHOEP
Number of subjects: 275
Study 23168367 — intervention group
Group type: COMPARATOR
Intervention: R-CHOEP-14
Number of subjects: 275
Study 19762332 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 127
Study 17850608 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 20% benzocaine gel
Number of subjects: 21
Study 17850608 — intervention group
Group type: COMPARATOR
Intervention: Injected 2% lidocaine
Number of subjects: 21
Study 16117898 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE instruction group (132,979 women)
Number of subjects: 266064
Study 16117898 — intervention group
Group type: COMPARATOR
Intervention: Control group (133,085 women)
Number of subjects: 266064
Study 11817993 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 482
Study 11817993 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate
Number of subjects: 482
Study 11817993 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 482
Study 10636366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg daily for 50 days)
Number of subjects: 123
Study 10636366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 7751733 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Lomefloxacin (LFLX)
Number of subjects: 119
Study 7751733 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Lomefloxacin (LFLX)
Number of subjects: 119
Study 2143361 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (Clarityn) 10 mg once daily
Number of subjects: 155
Study 2143361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (Tavegyl) 1 mg twice daily
Number of subjects: 155
Study 2143361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 31844063 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium + Dolosigranulum cluster at randomization (RD)
Number of subjects: 319
Study 31844063 — intervention group
Group type: EXPERIMENTAL
Intervention: Moraxella cluster at yellow zone (YZ)
Number of subjects: 319
Study 31844063 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium relative abundance at YZ
Number of subjects: 319
Study 28704156 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-NOSF matrix foam dressing (UrgoStart)
Number of subjects: 187
Study 28704156 — intervention group
Group type: COMPARATOR
Intervention: Control dressing (neutral TLC foam dressing, UrgoTul Absorb)
Number of subjects: 187
Study 26585638 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT by non-physician providers and medical assistants (NPP and MA arm)
Number of subjects: 54
Study 26585638 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT by physicians (PCP arm)
Number of subjects: 54
Study 26585638 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control arm)
Number of subjects: 54
Study 23924389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU daily) in DMT2 patients
Number of subjects: 499
Study 23924389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 499
Study 23924389 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Oral agents
Number of subjects: 499
Study 23924389 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 499
Study 23924389 — intervention group
Group type: COMPARATOR
Intervention: Control group (Non-DMT2)
Number of subjects: 499
Study 23924389 — intervention group
Group type: EXPERIMENTAL
Intervention: All DMT2 groups
Number of subjects: 499
Study 20585342 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 374
Study 20585342 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 374
Study 20585342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 20134050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen breathing during mild resistive loading
Number of subjects: 8
Study 20134050 — intervention group
Group type: COMPARATOR
Intervention: Air breathing during mild resistive loading
Number of subjects: 8
Study 20134050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen breathing during heavy resistive loading
Number of subjects: 8
Study 20134050 — intervention group
Group type: COMPARATOR
Intervention: Air breathing during heavy resistive loading
Number of subjects: 8
Study 17241415 — intervention group
Group type: EXPERIMENTAL
Intervention: Reloxin (Dysport, 20 U)
Number of subjects: 0
Study 17241415 — intervention group
Group type: EXPERIMENTAL
Intervention: Reloxin (Dysport, 50 U)
Number of subjects: 0
Study 17241415 — intervention group
Group type: EXPERIMENTAL
Intervention: Reloxin (Dysport, 75 U)
Number of subjects: 0
Study 17241415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15500940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish gelatin (3.61 g cumulative dose)
Number of subjects: 30
Study 15500940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish gelatin (7.61 g cumulative dose)
Number of subjects: 30
Study 15500940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11571495 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-limb endurance exercise training for 9 weeks
Number of subjects: 5
Study 9610900 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim in MOPP arm
Number of subjects: 47
Study 9610900 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim in MOPP/EVAP arm
Number of subjects: 47
Study 9610900 — intervention group
Group type: COMPARATOR
Intervention: Control (no filgrastim) in MOPP arm
Number of subjects: 47
Study 9610900 — intervention group
Group type: COMPARATOR
Intervention: Control (no filgrastim) in MOPP/EVAP arm
Number of subjects: 47
Study 7846367 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 20
Study 7846367 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) followed by Endotracheal Tube (ETT)
Number of subjects: 20
Study 7846367 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 20
Study 3292699 — intervention group
Group type: EXPERIMENTAL
Intervention: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(7.9) EID50/ml
Number of subjects: 0
Study 3292699 — intervention group
Group type: EXPERIMENTAL
Intervention: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(7.25) EID50/ml
Number of subjects: 0
Study 3292699 — intervention group
Group type: EXPERIMENTAL
Intervention: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(5.7) EID50/ml
Number of subjects: 0
Study 3292699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29269805 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% DMSO
Number of subjects: 150
Study 29269805 — intervention group
Group type: COMPARATOR
Intervention: 10% DMSO
Number of subjects: 150
Study 29269805 — intervention group
Group type: COMPARATOR
Intervention: 7.5% DMSO
Number of subjects: 150
Study 28403648 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple-boysenberry beverage
Number of subjects: 0
Study 28403648 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/16 dilution of apple-boysenberry beverage
Number of subjects: 0
Study 28403648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26091455 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented coping
Number of subjects: 117
Study 26091455 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-oriented coping
Number of subjects: 117
Study 26091455 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance-oriented coping
Number of subjects: 117
Study 26091455 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping styles
Number of subjects: 117
Study 26091455 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout syndrome incidence
Number of subjects: 117
Study 23327838 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 51
Study 23327838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 20348487 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose-doxycycline (SDD)
Number of subjects: 128
Study 20348487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 18429536 — intervention group
Group type: EXPERIMENTAL
Intervention: New device for urethral catheterization
Number of subjects: 0
Study 18429536 — intervention group
Group type: EXPERIMENTAL
Intervention: Comments from patients and nurses regarding the device
Number of subjects: 0
Study 16557618 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-identified risk cues
Number of subjects: 0
Study 14578732 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of ursodeoxycholic acid daily for 6 months
Number of subjects: 152
Study 14578732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 10963247 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 voluntary counselling and testing (VCT)
Number of subjects: 10000
Study 10963247 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 voluntary counselling and testing (VCT) targeting couples
Number of subjects: 10000
Study 10963247 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 voluntary counselling and testing (VCT) targeting high prevalence
Number of subjects: 10000
Study 8970280 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 gm supplement of All Bran and natural bran
Number of subjects: 0
Study 8970280 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1473667 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg starting dose, titrated incrementally)
Number of subjects: 0
Study 1473667 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.10 mg/kg starting dose, titrated incrementally)
Number of subjects: 0
Study 6327927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment with reinduction chemotherapy
Number of subjects: 453
Study 6327927 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone
Number of subjects: 453
Study 6327927 — intervention group
Group type: COMPARATOR
Intervention: Three different chemotherapy regimens for remission induction
Number of subjects: 453
Study 6327927 — intervention group
Group type: COMPARATOR
Intervention: Omission of chest irradiation
Number of subjects: 453
Study 6327927 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis by institutional pathologist
Number of subjects: 453
Study 30315403 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based or group-based exercise (twice weekly for 1 year)
Number of subjects: 194
Study 26966867 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD) patients (both PD and HD)
Number of subjects: 27232
Study 26966867 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 27232
Study 26966867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 27232
Study 26966867 — intervention group
Group type: COMPARATOR
Intervention: Control group (without kidney disease)
Number of subjects: 27232
Study 25487431 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (UFP, O₃) during cycling
Number of subjects: 53
Study 25487431 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (O₃) during cycling
Number of subjects: 53
Study 25487431 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal exposure to PM(2.5)
Number of subjects: 53
Study 25487431 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional PM(2.5) concentrations
Number of subjects: 53
Study 22495338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation, physical activity, and socialization (active treatment group)
Number of subjects: 14
Study 22495338 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 20214807 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical coordination training or cognitive behavioral theory based training (CBTr) for cleaners
Number of subjects: 0
Study 20214807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical exercise training, CBTr, and diet for health-care workers
Number of subjects: 0
Study 20214807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention for construction workers
Number of subjects: 0
Study 20214807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical exercise training, CBTr, and participatory ergonomics for industrial workers
Number of subjects: 0
Study 17659768 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete nouns
Number of subjects: 0
Study 17659768 — intervention group
Group type: EXPERIMENTAL
Intervention: All word classes and ambiguity conditions
Number of subjects: 0
Study 17659768 — intervention group
Group type: COMPARATOR
Intervention: Syntactically and semantically ambiguous items used as verbs
Number of subjects: 0
Study 16379430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini decoction
Number of subjects: 65
Study 16379430 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 65
Study 12939888 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS) group
Number of subjects: 141
Study 12939888 — intervention group
Group type: COMPARATOR
Intervention: Non-CFS chronic fatigue group
Number of subjects: 141
Study 10322592 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric isokinetic torque of plantar flexion (PF) at velocities of 30 degrees.s‐1, 60 degrees.s‐1, 120 degrees.s‐1, and 180 degrees.s‐1
Number of subjects: 81
Study 10322592 — intervention group
Group type: EXPERIMENTAL
Intervention: Angular delay at 180 degrees.s‐1
Number of subjects: 81
Study 10322592 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of age with peak and mean torques
Number of subjects: 81
Study 10322592 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of age with angular delay
Number of subjects: 81
Study 10322592 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of age with maximal passive dorsiflexion (DF) angle and torque
Number of subjects: 81
Study 10322592 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of age with peak torque velocity at 180 degrees.s‐1
Number of subjects: 81
Study 9279998 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of village health volunteers
Number of subjects: 1313
Study 9279998 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 1313
Study 2001067 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 10
Study 2001067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 6390445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of adriamycin
Number of subjects: 0
Study 30416026 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 68
Study 30416026 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 68
Study 28240592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 6092
Study 28240592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 6092
Study 28240592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID in LTE studies
Number of subjects: 6092
Study 28240592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID in LTE studies
Number of subjects: 6092
Study 25029428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering prednisolone for 6 months
Number of subjects: 181
Study 25029428 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for 3 months followed by matching-placebo for 3 months
Number of subjects: 181
Study 22716268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia (text and image) presentation
Number of subjects: 240
Study 22716268 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-only presentation
Number of subjects: 240
Study 22716268 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-only presentation
Number of subjects: 240
Study 22716268 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated information)
Number of subjects: 240
Study 21483385 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (3 mg) before incision (MO1 group)
Number of subjects: 40
Study 21483385 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline before incision and morphine after wound closure (MO2 group)
Number of subjects: 40
Study 19760046 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 143
Study 19760046 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral feeding (TOF)
Number of subjects: 143
Study 19760046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea and vomiting, analgesic and antiemetic requirement, level of pain, quality of life
Number of subjects: 143
Study 16816557 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine
Number of subjects: 709
Study 16816557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study 14530809 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (docetaxel, doxorubicin, cyclophosphamide) 75/50/500 mg/m2 6xq3wk
Number of subjects: 61
Study 14530809 — intervention group
Group type: COMPARATOR
Intervention: FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) 500/50/500 mg/m2 6x q3wk
Number of subjects: 61
Study 11708695 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist heat pack application for 20 minutes
Number of subjects: 30
Study 11708695 — intervention group
Group type: COMPARATOR
Intervention: Static stretching for 30 seconds
Number of subjects: 30
Study 9145856 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosidine sulfate (12 mg/kg)
Number of subjects: 16